HDAC9 and neoplasm: Preclinical studies have revealed that histone deacetylase (HDAC) inhibitors modulate the activation state of the APCs to effectively prime naive Ag-specific CD4+ T cells and restore the responsiveness of tolerant T cells isolated from tumor-bearing mice15.